{"entity":{"id":"nct04082364","kind":"trial","name":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","aka":[],"tldr":"A phase 2/3 trial of Margetuximab, Retifanlimab and Trastuzumab in HER2-positive gastric cancer, run by MacroGenics, completed.","summary":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer is a phase 2/3 interventional study registered as NCT04082364 by MacroGenics, with 82 participants recorded, started 2019-09-30 and reaching its primary completion in 2024-01-15. Interventions recorded: margetuximab, Retifanlimab, Tebotelimab, Trastuzumab, Chemotherapy. Conditions recorded: Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer.\n\nLinked to the drug Margetuximab because the registry names it among its interventions and HER2-positive gastric cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04082364","url":"https://clinicaltrials.gov/study/NCT04082364"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["margetuximab","retifanlimab","trastuzumab"],"companies":["macrogenics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04082364","phase":"2/3","setting":"A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer","sponsor":"MacroGenics","participation":[{"nct":"NCT04082364","source":"https://clinicaltrials.gov/study/NCT04082364","fetchedAt":"2026-10-07T16:53:13.478Z","studySha256":"1bcfdfd863889fc591603293c39c311f71920da0e38ecba9adc5edee25154af0","overallStatus":"COMPLETED","lastUpdatePosted":"2025-06-08","leadSponsor":"MacroGenics","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":82,"enrolmentType":"ACTUAL","siteCount":73,"recruitingSiteCount":0,"countries":["China","Germany","Italy","Poland","Singapore","South Korea","Taiwan","United Kingdom","United States"]}],"started":"2019-09-30","startedType":"actual","yearReported":2025,"enrolled":82,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective Response Rate (ORR) for Non-microsatellite Instability-high (Non-MSI-H) Participants (Cohort A) Using Investigator-assessed Radiology Reviews","primary":true,"unit":"%","arms":[{"name":"Chemotherapy-free Arm","n":48,"value":52.1,"note":"95% CI 37.2 to 66.7; Figures from the ClinicalTrials.gov results section (first posted 2025-04-22), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04082364?tab=results"}]},"route":"/trials/nct04082364/","neighbours":{"cancer":[{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/"}],"drug":[{"id":"margetuximab","kind":"drug","name":"Margetuximab","route":"/drugs/margetuximab/"},{"id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"company":[{"id":"macrogenics","kind":"company","name":"MacroGenics","route":"/companies/macrogenics/"}]}}